GlucoTrack Inc (GCTK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlucoTrack Inc (GCTK) has a cash flow conversion efficiency ratio of 4.757x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.05 Million) by net assets ($-851.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GlucoTrack Inc (GCTK) market capitalisation for the company's overall valuation and market capitalisation.
GlucoTrack Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how GlucoTrack Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GlucoTrack Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlucoTrack Inc ranked by their cash flow conversion efficiency. Explore GCTK cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Searchlight Resources Inc
V:SCLT
|
-0.141x |
|
Imprimerie Chirat Société Anonyme
PA:MLIMP
|
N/A |
|
Williamson Magor & Company Limited
NSE:WILLAMAGOR
|
-0.196x |
|
Flow Beverage Corp
TO:FLOW
|
0.038x |
|
Aberdeen International Inc.
TO:AAB
|
-0.705x |
|
Telo Genomics Corp
V:TELO
|
11.261x |
|
ACRUX Ltd
AU:ACR
|
-3.930x |
|
DGB Asia Bhd
KLSE:0152
|
0.007x |
Annual Cash Flow Conversion Efficiency for GlucoTrack Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of GlucoTrack Inc from 2011 to 2025. View GlucoTrack Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.83 Million | $-15.24 Million | -5.389x | -660.90% |
| 2024-12-31 | $-13.00 Million | $-12.49 Million | 0.961x | +146.84% |
| 2023-12-31 | $3.20 Million | $-6.56 Million | -2.051x | +32.34% |
| 2022-12-31 | $1.23 Million | $-3.73 Million | -3.032x | -314.66% |
| 2021-12-31 | $5.16 Million | $-3.77 Million | -0.731x | -87.58% |
| 2020-12-31 | $8.98 Million | $-3.50 Million | -0.390x | -114.12% |
| 2019-12-31 | $-1.41 Million | $-3.90 Million | 2.761x | +62.18% |
| 2018-12-31 | $-2.87 Million | $-4.89 Million | 1.703x | +378.73% |
| 2017-12-31 | $-16.57 Million | $-5.90 Million | 0.356x | -26.69% |
| 2016-12-31 | $-10.95 Million | $-5.31 Million | 0.485x | -25.92% |
| 2015-12-31 | $-6.97 Million | $-4.57 Million | 0.655x | -5.86% |
| 2014-12-31 | $-4.83 Million | $-3.36 Million | 0.696x | +139.18% |
| 2013-12-31 | $-11.06 Million | $-3.22 Million | 0.291x | -93.63% |
| 2012-12-31 | $-503.07K | $-2.30 Million | 4.566x | +330.72% |
| 2011-12-31 | $968.24K | $-1.92 Million | -1.979x | -- |
About GlucoTrack Inc
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications… Read more